Celldex Therapeutics Ownership | Who Owns Celldex Therapeutics?

Overview Forecast RevenueFinancials Chart

Celldex Therapeutics Ownership Summary

Celldex Therapeutics is owned by 108.33% institutional investors, 0.32% insiders. Wellington management group llp is the largest institutional shareholder, holding 13.72% of CLDX shares. Vanguard Health Care Inv is the top mutual fund, with 6.85% of its assets in Celldex Therapeutics shares.

CLDX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Celldex Therapeutics	108.33%	0.32%	-8.64%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Wellington management group llp	8.08M	13.72%	$298.89M
Fmr	7.83M	13.30%	$289.76M
Blackrock	4.69M	7.97%	$173.61M
Vanguard group	3.74M	6.35%	$138.38M
Kynam capital management, lp	3.39M	5.76%	$125.43M
Eventide asset management	3.33M	5.65%	$123.14M
Price t rowe associates inc /md/	3.17M	5.39%	$117.41M
Polar capital	3.08M	5.23%	$113.87M
Bellevue group	2.97M	5.05%	$109.98M
State street	2.66M	4.52%	$98.41M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Kynam capital management, lp	3.39M	9.67%	$125.43M
5am venture management	497.27K	4.12%	$18.40M
Commodore capital lp	1.43M	3.60%	$52.74M
Silverarc capital management	374.91K	3.27%	$13.88M
Tsp capital management group	249.22K	2.89%	$9.22M
Eventide asset management	3.33M	2.11%	$123.14M
Affinity asset advisors	475.40K	2.03%	$17.59M
Bellevue group	2.97M	1.79%	$109.98M
Redmile group	718.72K	1.61%	$26.60M
Eversept partners, lp	633.01K	1.60%	$23.43M

Top Buyers

Holder	Shares	% Assets	Change
Novo	850.00K	1.58%	850.00K
Point72 asset management	1.94M	0.19%	654.19K
Commodore capital lp	1.43M	3.60%	558.53K
Kynam capital management, lp	3.39M	9.67%	488.97K
Marshall wace, llp	1.38M	0.07%	479.07K

Top Sellers

Holder	Shares	% Assets	Change
Fmr	7.83M	0.02%	-1.90M
Logos global management lp	-	-	-650.00K
Sofinnova investments	-	-	-547.71K
State street	2.66M	0.00%	-320.66K
Candriam s.c.a.	-	-	-317.51K

New Positions

Holder	Shares	% Assets	Change	Value
Novo	850.00K	1.58%	850.00K	$31.46M
Panagora asset management	118.35K	0.02%	118.35K	$4.38M
Artia global partners lp	75.30K	0.54%	75.30K	$2.79M
Capital fund management	44.45K	0.00%	44.45K	$1.64M
Mirae asset global etfs	35.41K	0.00%	35.41K	$1.31M

Sold Out

Holder	Change
Scarborough advisors	-6.00
Nelson, van denburg & campbell wealth management group	-10.00
Householder group estate & retirement specialist	-11.00
Innealta capital	-17.00
Hartford financial management	-18.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	199	6.42%	71,815,551	3.19%	108	0.78%	95	-8.65%	55	14.58%
Jun 30, 2024	187	-8.33%	69,597,419	0.41%	118	0.85%	104	-18.75%	48	11.63%
Mar 31, 2024	204	15.25%	69,309,919	13.65%	117	0.86%	128	40.66%	43	-10.42%
Dec 31, 2023	177	12.03%	60,984,745	20.59%	117	1.02%	91	15.19%	48	14.29%
Sep 30, 2023	158	-1.86%	50,572,751	0.41%	107	0.94%	79	1.28%	42	-8.70%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Health Care Inv	4.54M	6.85%	1.17M
BB Biotech AG Ord	3.07M	4.63%	100.00K
Vanguard Total Stock Mkt Idx Inv	2.09M	3.15%	22.02K
iShares Russell 2000 ETF	1.80M	2.71%	-3.75K
Eventide Gilead N	1.76M	2.65%	206.37K
Eventide Healthcare & Life Sciences I	1.56M	2.35%	-
Polar Capital Biotech S Inc	1.25M	1.88%	-
Polar Capital Healthcare Opports Inc	1.15M	1.73%	-
Vanguard Explorer Inv	1.13M	1.71%	-
T. Rowe Price New Horizons	1.05M	1.59%	-3.31K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 11, 2024	Marucci Anthony S	PRESIDENT & CEO	Buy	$308.43K
Jun 14, 2024	Martin Samuel Bates	SVP AND CFO	Sell	$608.31K
Jun 14, 2024	Crowley Elizabeth	SR. VP & CPDO	Sell	$1.05M
Jun 07, 2024	Crowley Elizabeth	SR. VP & CPDO	Sell	$525.87K
Jun 07, 2024	Young Diane C.	SVP, CHIEF MEDICAL OFFICER	Sell	$1.59M

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	1	-
2024 Q2	-	12
2024 Q1	-	-
2023 Q2	-	-
2023 Q1	-	-

CLDX Ownership FAQ

Who Owns Celldex Therapeutics?

Celldex Therapeutics shareholders are primarily institutional investors at 108.33%, followed by 0.32% insiders and -8.65% retail investors. The average institutional ownership in Celldex Therapeutics's industry, Biotech Stocks , is 47.04%, which Celldex Therapeutics exceeds.

Who owns the most shares of Celldex Therapeutics?

Celldex Therapeutics’s largest shareholders are Wellington management group llp (8.08M shares, 13.72%), Fmr (7.83M shares, 13.30%), and Blackrock (4.69M shares, 7.97%). Together, they hold 34.98% of Celldex Therapeutics’s total shares outstanding.

Does Blackrock own Celldex Therapeutics?

Yes, BlackRock owns 7.97% of Celldex Therapeutics, totaling 4.69M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 173.61M$. In the last quarter, BlackRock increased its holdings by 178.84K shares, a 3.96% change.

Who is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.67% of its assets in 3.39M Celldex Therapeutics shares, valued at 125.43M$.

Who is the top mutual fund holder of Celldex Therapeutics shares?

Vanguard Health Care Inv is the top mutual fund holder of Celldex Therapeutics shares, with 6.85% of its total shares outstanding invested in 4.54M Celldex Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools